Guggenheim Begins Coverage on Assembly Biosciences (NASDAQ:ASMB)

Research analysts at Guggenheim began coverage on shares of Assembly Biosciences (NASDAQ:ASMB – Get Free Report) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $31.00 price target on the biopharmaceutical company’s stock. Guggenheim’s target price points to a potential upside of 186.77% from the […]

Leave a Reply

Your email address will not be published.

Previous post Bruins keep on losing, drop 6-2 decision to Anaheim
Next post CrowdStrike (NASDAQ:CRWD) Upgraded at BTIG Research